Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.

[1]  R. Montironi,et al.  Increased androgen receptor gene copy number is associated with TMPRSS2‐ERG rearrangement in prostatic small cell carcinoma , 2015, Molecular carcinogenesis.

[2]  Kenya Yamaguchi,et al.  Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy , 2014, Scandinavian journal of urology.

[3]  B. Sarbay,et al.  Significance of the cribriform pattern in prostatic adenocarcinomas. , 2014, Pathology, research and practice.

[4]  Yezi Zhu,et al.  Interleukin‐6 induces neuroendocrine differentiation (NED) through suppression of RE‐1 silencing transcription factor (REST) , 2014, The Prostate.

[5]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[6]  E. Davicioni,et al.  Effect of enzalutamide (EZ) exposure time on androgen receptor (AR) splice variant (SV) expression and gene transcription correlates in androgen-dependent (AD) prostate cancer (PC) cells. , 2014 .

[7]  V. Calvo,et al.  Neuroendocrine differentiation in carcinoma of the prostate: An institutional review. , 2014 .

[8]  M. Kohli,et al.  Neuroendocrine differentiation patterns in metastases from advanced prostate cancer. , 2014 .

[9]  M. Rubin,et al.  Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[10]  Jiaoti Huang,et al.  Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation , 2014, Asian journal of andrology.

[11]  J. Machiels,et al.  A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[12]  J. Epstein,et al.  Small cell carcinoma of the prostate , 2014, Nature Reviews Urology.

[13]  H. Kung,et al.  Autophagy Pathway Is Required for IL-6 Induced Neuroendocrine Differentiation and Chemoresistance of Prostate Cancer LNCaP Cells , 2014, PloS one.

[14]  David C. Smith,et al.  A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). , 2014 .

[15]  H. Beltran,et al.  Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC). , 2014 .

[16]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[17]  H. Beltran,et al.  Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. , 2013, Neoplasia.

[18]  G. Amorino,et al.  Neuroendocrine‐derived peptides promote prostate cancer cell survival through activation of IGF‐1R signaling , 2013, The Prostate.

[19]  P. Thall,et al.  Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[20]  Yan Geng,et al.  p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia , 2013, Proceedings of the National Academy of Sciences.

[21]  T. Tsuzuki,et al.  The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. , 2013, Molecular and clinical oncology.

[22]  R. Cardiff,et al.  Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell of origin model for prostate cancer heterogeneity , 2013, Nature Cell Biology.

[23]  J. Haefliger,et al.  Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. , 2013, Endocrine-related cancer.

[24]  F. Cappuzzo,et al.  Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure , 2013, BJU international.

[25]  C. Blanpain,et al.  Multipotent and unipotent progenitors contribute to prostate postnatal development , 2012, Nature Cell Biology.

[26]  J. Gordon,et al.  G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. , 2012, The Tohoku journal of experimental medicine.

[27]  Emily J. Girard,et al.  Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model , 2012, British Journal of Cancer.

[28]  V. Weinberg,et al.  Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. , 2012, Urologic oncology.

[29]  C. Liang,et al.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. , 2012, Endocrine-related cancer.

[30]  M. Farach-Carson,et al.  Interleukin-6 , 2012, Autophagy.

[31]  J. Donovan,et al.  Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population‐based study , 2012, BJU international.

[32]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.

[33]  C. Bieberich,et al.  ERG gene rearrangements are common in prostatic small cell carcinomas , 2011, Modern Pathology.

[34]  K. Macleod.  The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer? , 2010, The Journal of clinical investigation.

[35]  Y. Na,et al.  Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer , 2010, Oncogene.

[36]  P. Magni,et al.  Regulation of prostate cancer cell proliferation by somatostatin receptor activation , 2010, Molecular and Cellular Endocrinology.

[37]  C. Moran,et al.  Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. , 2009, Archives of pathology & laboratory medicine.

[38]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[39]  E. Dahl,et al.  Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer , 2009, BMC Cancer.

[40]  A. Lopez‐Beltran,et al.  Neuroendocrine tumours of the urinary system and male genital organs: clinical significance , 2009, BJU international.

[41]  Jason K. Wang,et al.  Neuroendocrine differentiation of prostate cancer. , 2013, Asian journal of andrology.

[42]  W. Oh,et al.  CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. , 2009, Human pathology.

[43]  E. Gelmann,et al.  R E V Ie W a Rt I C L E , 2022 .

[44]  J. Epstein,et al.  Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases , 2008, The American journal of surgical pathology.

[45]  W. Delprado,et al.  Carcinoid tumors of the urinary tract and prostate. , 2006, Archives of pathology & laboratory medicine.

[46]  C. Mitsiades,et al.  Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. , 2006, Anticancer research.

[47]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[48]  J. Epstein,et al.  Prognostic Significance of Paneth Cell-like Neuroendocrine Differentiation in Adenocarcinoma of the Prostate , 2006, The American journal of surgical pathology.

[49]  A. Evans,et al.  Large Cell Neuroendocrine Carcinoma of Prostate: A Clinicopathologic Summary of 7 Cases of a Rare Manifestation of Advanced Prostate Cancer , 2006, The American journal of surgical pathology.

[50]  C. Mitsiades,et al.  RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER , 2006 .

[51]  Kenneth J. Pienta,et al.  Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer , 2006, Clinical Cancer Research.

[52]  C. Bieberich,et al.  Distinct regulatory elements mediate the dynamic expression pattern of Nkx3.1 , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

[53]  P. di Sant'Agnese,et al.  Regulation of interleukin‐6‐mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells , 2004, The Prostate.

[54]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[55]  D. Bostwick,et al.  Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. , 2002, The Journal of urology.

[56]  L. Dogliotti,et al.  Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin‐A, prostate‐specific antigen, and insulin‐like growth factor‐1 in advanced prostate cancer patients , 2001, The Prostate.

[57]  R. Montironi,et al.  Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.

[58]  C. Dinney,et al.  Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  J. Quinn,et al.  A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. , 2000, Cancer research.

[60]  T. Chung,et al.  STAT3 mediates IL‐6‐induced neuroendocrine differentiation in prostate cancer cells , 2000, The Prostate.

[61]  G. Murphy,et al.  Circulating levels of interleukin‐6 in patients with hormone refractory prostate cancer , 1999, The Prostate.

[62]  J. Mackey,et al.  Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. , 1998, The Journal of urology.

[63]  A. Bjartell,et al.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.

[64]  H. Kung,et al.  Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  H. Frierson,et al.  Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.

[66]  P. Blitzer,et al.  Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. , 1997, American journal of clinical oncology.

[67]  M. Shen,et al.  Tissue‐specific expression of murine Nkx3.1 in the male urogenital system , 1997, Developmental dynamics : an official publication of the American Association of Anatomists.

[68]  C. Bieberich,et al.  Prostate-specific and Androgen-dependent Expression of a Novel Homeobox Gene* , 1996, The Journal of Biological Chemistry.

[69]  A. Partin,et al.  Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.

[70]  D. Bostwick,et al.  Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. , 1994, Human pathology.

[71]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .

[72]  C. Logothetis,et al.  Chemotherapy for small cell carcinoma of prostatic origin. , 1992, The Journal of urology.

[73]  D. Bostwick,et al.  Paneth Cell‐like Change of the Prostate Gland: A Histological, Immunohistochemical, and Electron Microscopic Study , 1991, The American journal of surgical pathology.

[74]  M. Nirenberg,et al.  Drosophila NK-homeobox genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[75]  V. Ghali,et al.  Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Immunohistochemical study and review of the literature , 1984, Cancer.

[76]  M. Rubin,et al.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.

[77]  B. Czerniak,et al.  TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. , 2011, Human pathology.

[78]  M. Henriksson,et al.  MYC in oncogenesis and as a target for cancer therapies. , 2010, Advances in cancer research.

[79]  R. Cardiff,et al.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. , 2008, The American journal of pathology.

[80]  M. Ahel,et al.  Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. , 2002, Anticancer research.

[81]  R. Vessella,et al.  Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. , 1999, Urology.